Frederick, Colo.
Agilent Technologies will begin construction in fall of 2016 on a 130,000-sf pharmaceutical manufacturing facility in Frederick, Colo. Doubling the life science company's commercial production capacity for oligonucleotides, the project will support the creation of therapies based on nucleic acid active pharmaceutical ingredients (APIs). Agilent is based in Santa Clara, Calif.
